PAREXEL Named a 2015 Flexjobs “Top 100 Company for Remote Jobs”
BOSTON, March 17, 2015 —PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has been named for the second consecutive year to the FlexJobs Top 100 Companies to Watch for Remote Jobs in 2015. The list recognizes companies with flexible job opportunities and is intended to guide job seekers in their search for companies with a successful track record of recruiting and hiring telecommuters.
PAREXEL offers nearly 20 percent of its global employees flexible work options, including telecommuting, flexible schedules, and home-based employment. In North America, more than 40 percent of PAREXEL’s employees take advantage of flexible employment opportunities. These employees represent a diverse cross section of positions, including clinical research, biostatistics, and regulatory affairs.
“We understand that in today’s fast-paced, globally connected world, employment flexibility can lead to a more engaged, more satisfied workforce – both key to PAREXEL providing the highest level of client satisfaction,” said Tom McGoldrick, Vice President of Talent Acquisition, PAREXEL. “PAREXEL’s varied work options also provide access to a skilled labor force without geographic restrictions, which is essential for meeting organizational growth and helping our clients simplify their journey towards bringing new treatments to the patients who need them around the world.”
About the Ranking
FlexJobs, a job service specializing in remote and flexible job opportunities, analyzed its database of over 30,000 companies’ job posting history from the prior year to determine which companies would be most likely to incorporate telecommuting into their 2015 hiring practices. In 2015, PAREXEL ranked 17th in the top 100.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 81 locations in 51 countries around the world, and has approximately 16,530 employees. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisition of ClinIntel Limited, or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2014 as filed with the Securities and Exchange Commission on February 5, 2015, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.